SI2772535T1 - ABC5 pozitivne mezenhimske matične celice kot imunomodulatorji - Google Patents

ABC5 pozitivne mezenhimske matične celice kot imunomodulatorji

Info

Publication number
SI2772535T1
SI2772535T1 SI200732189T SI200732189T SI2772535T1 SI 2772535 T1 SI2772535 T1 SI 2772535T1 SI 200732189 T SI200732189 T SI 200732189T SI 200732189 T SI200732189 T SI 200732189T SI 2772535 T1 SI2772535 T1 SI 2772535T1
Authority
SI
Slovenia
Prior art keywords
abc5
immunomodulators
stem cells
mesenchymal stem
positive mesenchymal
Prior art date
Application number
SI200732189T
Other languages
English (en)
Inventor
Markus H Frank
Original Assignee
Children's Medical Center Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Children's Medical Center Corporation filed Critical Children's Medical Center Corporation
Publication of SI2772535T1 publication Critical patent/SI2772535T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0668—Mesenchymal stem cells from other natural sources
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0625—Epidermal cells, skin cells; Cells of the oral mucosa
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/36—Skin; Hair; Nails; Sebaceous glands; Cerumen; Epidermis; Epithelial cells; Keratinocytes; Langerhans cells; Ectodermal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
SI200732189T 2006-05-31 2007-05-31 ABC5 pozitivne mezenhimske matične celice kot imunomodulatorji SI2772535T1 (sl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US80940706P 2006-05-31 2006-05-31
EP14168199.9A EP2772535B1 (en) 2006-05-31 2007-05-31 ABC5 positive mesenchymal stem cells as immunomodulators

Publications (1)

Publication Number Publication Date
SI2772535T1 true SI2772535T1 (sl) 2022-08-31

Family

ID=38594403

Family Applications (2)

Application Number Title Priority Date Filing Date
SI200732189T SI2772535T1 (sl) 2006-05-31 2007-05-31 ABC5 pozitivne mezenhimske matične celice kot imunomodulatorji
SI200731523T SI2035549T1 (sl) 2006-05-31 2007-05-31 ABCB5 pozitivne mezenhimske matične celice kot imunomodulatorji

Family Applications After (1)

Application Number Title Priority Date Filing Date
SI200731523T SI2035549T1 (sl) 2006-05-31 2007-05-31 ABCB5 pozitivne mezenhimske matične celice kot imunomodulatorji

Country Status (13)

Country Link
US (4) US8455245B2 (sl)
EP (2) EP2772535B1 (sl)
AU (1) AU2007254894B9 (sl)
CA (1) CA2685492C (sl)
DK (2) DK2035549T3 (sl)
ES (2) ES2918323T3 (sl)
HK (2) HK1129703A1 (sl)
HU (1) HUE059011T2 (sl)
LT (1) LT2772535T (sl)
PL (2) PL2035549T3 (sl)
PT (2) PT2035549E (sl)
SI (2) SI2772535T1 (sl)
WO (1) WO2007143139A1 (sl)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3333182A1 (en) 2000-06-05 2018-06-13 The Brigham and Women's Hospital, Inc. A gene encoding a multidrug resistance human p-glycoprotein homologue on chromosome 7p15-21 and uses thereof
DK2035549T3 (da) 2006-05-31 2014-10-13 Childrens Medical Center Abcb5-positive mesenkymale stamceller som immunmodulatorer
JP5889527B2 (ja) 2007-04-12 2016-03-22 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ， Ｉｎｃ． 癌療法のためのａｂｃｂ５標的化
EP3978928A1 (en) 2008-11-14 2022-04-06 The Brigham and Women's Hospital, Inc. Therapeutic and diagnostic methods relating to cancer stem cells
US11542328B2 (en) 2008-11-14 2023-01-03 The Brigham And Women's Hospital, Inc. Therapeutic and diagnostic methods relating to cancer stem cells
KR102474489B1 (ko) * 2013-02-19 2022-12-06 칠드런'즈 메디컬 센터 코포레이션 안구 질환을 치료하기 위한 abcb5(+) 줄기 세포
AU2014262590B2 (en) * 2013-05-10 2018-05-10 Children's Medical Center Corporation Wound healing and tissue engineering
US20150310380A1 (en) * 2014-04-28 2015-10-29 Patent Investment & Licensing Company Dispatch system having control shared with dispatched service providers
KR101723265B1 (ko) * 2013-08-16 2017-04-04 가톨릭대학교 산학협력단 mTOR/STAT3 신호억제제 처리된 면역조절능을 갖는 간엽줄기세포 및 이를 포함하는 면역질환의 예방 또는 치료용 세포치료제 조성물
WO2015088414A1 (en) * 2013-12-13 2015-06-18 Isletone Ab Immunomodulatory compositions
US10739338B2 (en) 2014-03-24 2020-08-11 Qt Holdings Corp Shaped articles including hydrogels and methods of manufacture and use thereof
US9790467B2 (en) * 2015-09-22 2017-10-17 Qt Holdings Corp Methods and compositions for activation or expansion of T lymphocytes
MX2021001850A (es) * 2018-08-18 2021-07-15 Harvard College Edicion genica in situ.
US20200061365A1 (en) * 2018-08-24 2020-02-27 Instant Systems, Inc. Cell storage container for use with sterile docking systems
EP3946389A4 (en) * 2019-03-28 2023-05-10 Children's Medical Center Corporation HIGHLY FUNCTIONAL PRODUCED ABCB5+ MESENCHYMATE STEM CELLS
CN114206359A (zh) * 2019-04-24 2022-03-18 儿童医学中心公司 用于肝病的abcb5+干细胞治疗
EP4125960A4 (en) * 2020-03-30 2024-04-03 Childrens Medical Center USE OF STEM CELLS FOR THE TREATMENT OF EXCESSIVE INFLAMMATION
EP4351721A1 (en) * 2021-05-13 2024-04-17 Primegen US, Inc. Methods and compositions for treating liver disease
US20230256065A1 (en) * 2022-02-16 2023-08-17 Elena RUSYN Autologous stem cell vaccine and methods

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4352883A (en) 1979-03-28 1982-10-05 Damon Corporation Encapsulation of biological material
EP0174810B1 (en) 1984-09-10 1993-07-21 HSC Research Development Corporation Multidrug resistance in mammalian cell lines and isolation of determinant glycoprotein dna
US4837306A (en) 1985-02-25 1989-06-06 The Ontario Cancer Institute Method for selecting hybridomas producing antibodies specific to the P-glycoprotein cell suface antigen and a cDNA clone encoding the C-terminal portion of the antigen
US5837258A (en) 1991-08-30 1998-11-17 University Of South Florida Induction of tissue, bone or cartilage formation using connective tissue growth factor
IT1257893B (it) 1992-06-17 1996-02-16 Ist Superiore Sanita Anticorpi monoclonali che riconoscono un epitopo della p-glicoproteina umana.
WO1994009363A1 (en) 1992-10-14 1994-04-28 Board Of Regents, The University Of Texas System Cancer diagnosis and therapy
US5906934A (en) 1995-03-14 1999-05-25 Morphogen Pharmaceuticals, Inc. Mesenchymal stem cells for cartilage repair
EP0906415B1 (en) 1996-04-19 2009-08-19 Osiris Therapeutics, Inc. Regeneration and augmentation of bone using mesenchymal stem cells
US6152142A (en) 1997-02-28 2000-11-28 Tseng; Scheffer C. G. Grafts made from amniotic membrane; methods of separating, preserving, and using such grafts in surgeries
DE69922933T2 (de) 1998-03-13 2005-12-29 Osiris Therapeutics, Inc. Anwendungen für humane nicht autologe, mesenchymale stammzellen
US6368636B1 (en) 1998-03-18 2002-04-09 Osiris Therapeutics, Inc. Mesenchymal stem cells for prevention and treatment of immune responses in transplantation
US6797269B2 (en) 1998-04-03 2004-09-28 Osiris Therapeutics, Inc. Mesenchymal stem cells as immunosuppressants
GB9808836D0 (en) 1998-04-27 1998-06-24 Amersham Pharm Biotech Uk Ltd Microfabricated apparatus for cell based assays
WO1999061587A1 (en) 1998-05-29 1999-12-02 Osiris Therapeutics, Inc. Human cd45+ and/or fibroblast + mesenchymal stem cells
EP3333182A1 (en) 2000-06-05 2018-06-13 The Brigham and Women's Hospital, Inc. A gene encoding a multidrug resistance human p-glycoprotein homologue on chromosome 7p15-21 and uses thereof
DE60140252D1 (de) 2000-06-22 2009-12-03 Genentech Inc Agonistische monoklonale antikörper gegen trkc
SE517275C2 (sv) * 2000-09-20 2002-05-21 Obducat Ab Sätt vid våtetsning av ett substrat
CA2427010A1 (en) 2000-10-27 2002-05-23 Incyte Genomics, Inc. Transporters and ion channels
US6905678B2 (en) 2001-07-07 2005-06-14 Crucell Holland B.V. Gene delivery vectors with cell type specificity for mesenchymal stem cells
AU2003281200A1 (en) 2002-07-03 2004-01-23 Tasuku Honjo Immunopotentiating compositions
AU2003288675B2 (en) 2002-12-23 2010-07-22 Medimmune Limited Antibodies against PD-1 and uses therefor
GB0325130D0 (en) 2003-10-28 2003-12-03 Smith & Nephew Apparatus with scaffold
CA2546942A1 (en) 2003-11-24 2005-06-16 The Rockefeller University A method for isolating a self-renewing, multipotent slow-cycling cell
RU2401277C2 (ru) 2004-01-07 2010-10-10 Чирон Корпорейшн Не мышиное анти-m-csf-антитело (варианты), его получение и использование
US20050186672A1 (en) 2004-01-27 2005-08-25 Reliance Life Sciences Pvt. Ltd. Tissue system with undifferentiated stem cells derived from corneal limbus
CA2998412C (en) 2004-11-12 2024-01-02 Cambridge University Technical Services Ltd. Methods and means related to cancer stem cells
WO2006103685A2 (en) 2005-03-28 2006-10-05 Vision Research Foundation A method for cultivating cells derived from corneal limbal tissue and cells deived from corneal limbal tissue
IL286053B2 (en) * 2005-10-18 2023-03-01 Nat Jewish Health A process for making red blood cells using immortal hematopoietic stem cells and erythropoietin
DK2035549T3 (da) 2006-05-31 2014-10-13 Childrens Medical Center Abcb5-positive mesenkymale stamceller som immunmodulatorer
EP2079484A4 (en) 2006-09-07 2010-03-17 Stemline Therapeutics Inc MONITORING OF CANCER STEM CELLS
JP5889527B2 (ja) 2007-04-12 2016-03-22 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ， Ｉｎｃ． 癌療法のためのａｂｃｂ５標的化
US9011840B2 (en) 2008-03-14 2015-04-21 The Board Of Trustees Of The University Of Illinois Activated mesenchymal stem cells for wound healing and impaired tissue regeneration
US11542328B2 (en) 2008-11-14 2023-01-03 The Brigham And Women's Hospital, Inc. Therapeutic and diagnostic methods relating to cancer stem cells
EP3978928A1 (en) 2008-11-14 2022-04-06 The Brigham and Women's Hospital, Inc. Therapeutic and diagnostic methods relating to cancer stem cells
KR102474489B1 (ko) 2013-02-19 2022-12-06 칠드런'즈 메디컬 센터 코포레이션 안구 질환을 치료하기 위한 abcb5(+) 줄기 세포
AU2014262590B2 (en) 2013-05-10 2018-05-10 Children's Medical Center Corporation Wound healing and tissue engineering
WO2019210109A1 (en) 2018-04-25 2019-10-31 Children's Medical Center Corporation Abcb5 ligands and substrates
EP3946389A4 (en) 2019-03-28 2023-05-10 Children's Medical Center Corporation HIGHLY FUNCTIONAL PRODUCED ABCB5+ MESENCHYMATE STEM CELLS

Also Published As

Publication number Publication date
CA2685492A1 (en) 2007-12-13
HK1129703A1 (en) 2009-12-04
LT2772535T (lt) 2022-08-25
DK2035549T3 (da) 2014-10-13
SI2035549T1 (sl) 2015-03-31
EP2772535B1 (en) 2022-04-06
US8455245B2 (en) 2013-06-04
HUE059011T2 (hu) 2022-09-28
AU2007254894B2 (en) 2014-10-23
US11624054B2 (en) 2023-04-11
US20080003206A1 (en) 2008-01-03
PT2772535T (pt) 2022-07-04
PL2035549T3 (pl) 2014-12-31
EP2772535A1 (en) 2014-09-03
PL2772535T3 (pl) 2022-09-05
US10017738B2 (en) 2018-07-10
WO2007143139A1 (en) 2007-12-13
US20230313136A1 (en) 2023-10-05
AU2007254894A1 (en) 2007-12-13
AU2007254894B9 (en) 2014-11-13
DK2772535T3 (da) 2022-07-04
ES2918323T3 (es) 2022-07-15
EP2035549B1 (en) 2014-07-09
PT2035549E (pt) 2014-10-06
CA2685492C (en) 2018-01-16
US20130315880A1 (en) 2013-11-28
ES2511791T3 (es) 2014-10-23
HK1201295A1 (en) 2015-08-28
EP2035549A1 (en) 2009-03-18
US20180320131A1 (en) 2018-11-08

Similar Documents

Publication Publication Date Title
SI2772535T1 (sl) ABC5 pozitivne mezenhimske matične celice kot imunomodulatorji
HK1216883A1 (zh) 幹細胞培養
PL2254586T3 (pl) Cząstki mezenchymalnych komórek macierzystych
EP2315829A4 (en) INDUCED PLURIPOTENT STEM CELLS
PL2046946T3 (pl) Hodowla pluripotencjalnych komórek macierzystych
GB2458863B (en) Improved culture of stem cells
SG10201500674YA (en) Pluripotent stem cells
GB0814249D0 (en) Uses of mesenchymal stem cells
EP1971679A4 (en) MESENCHYMAL STEM CELLS EXPRESSING TNF RECEPTOR
IL212368A0 (en) Compounds that expand hematopoietic stem cells
ZA201000715B (en) Single pluripotent stem cell culture
SG10201403202XA (en) Pre-natal mesenchymal stem cells
EP2007411A4 (en) REGULATORY STEM CELLS
EP2294182A4 (en) CULTS OF MULTIPOTENT STEM CELLS
EP2037960A4 (en) METHOD FOR MANIPULATING STEM CELLS
GB0602208D0 (en) Embryonic stem cells
GB0724994D0 (en) Mesenchymal stem cell markers
GB0818256D0 (en) stem cells
GB2467284B (en) Sulfatase enzymes
GB0918471D0 (en) Stem cells
IL193947A0 (en) Regulating stem cells